Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study

被引:53
作者
Lodi, Sara [1 ]
Phillips, Andrew [2 ]
Logan, Roger [1 ]
Olson, Ashley [3 ]
Costagliola, Dominique [4 ]
Abgrall, Sophie [4 ,5 ]
van Sighem, Ard [6 ]
Reiss, Peter [6 ,7 ,8 ,9 ]
Miro, Jose M. [10 ]
Ferrer, Elena [11 ]
Justice, Amy [12 ,13 ]
Gandhi, Neel [14 ,15 ,16 ]
Bucher, Heiner C. [17 ]
Furrer, Hansjakob [18 ,19 ]
Moreno, Santiago [20 ,21 ]
Monge, Susana [21 ]
Touloumi, Giota [22 ]
Pantazis, Nikos [22 ]
Sterne, Jonathan [23 ]
Young, Jessica G. [1 ]
Meyer, Laurence [24 ,25 ]
Seng, Remonie [24 ,25 ]
Dabis, Francois [26 ,27 ]
Vandehende, Marie-Anne [26 ,27 ]
Perez-Hoyos, Santiago [28 ,29 ]
Jarrin, Inma [28 ,30 ]
Jose, Sophie [2 ]
Sabin, Caroline [2 ]
Hernan, Miguel A. [1 ,31 ,32 ]
机构
[1] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[2] UCL, London, England
[3] UCL, Med Res Council Clin Trials Unit, London, England
[4] Univ Paris 06, Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, UMR S1136, Paris, France
[5] Hop Antoine Beclere, AP HP, Serv Med Interne, Clamart, France
[6] Stichting HIV Monitoring, Amsterdam, Netherlands
[7] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, NL-1105 AZ Amsterdam, Netherlands
[8] Univ Amsterdam, Acad Med Ctr, Div Infect Dis, NL-1105 AZ Amsterdam, Netherlands
[9] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands
[10] Univ Barcelona, Hosp Clin, IDIBAPS, Barcelona, Spain
[11] Univ Barcelona, Bellvitge Univ Hosp, Inst Invest Biomed Bellvitge IDIBELL, Lhospitalet De Llobregat, Spain
[12] Yale Univ, Sch Med, New Haven, CT USA
[13] VA Connecticut Healthcare Syst, West Haven, CT USA
[14] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA
[15] Emory Univ, Dept Global Hlth, Atlanta, GA 30322 USA
[16] Emory Univ, Dept Med, Atlanta, GA 30322 USA
[17] Univ Basel Hosp, Basel Inst Clin Epidemiol & Biostat, CH-4031 Basel, Switzerland
[18] Univ Hosp Bern, Dept Infect Dis, CH-3010 Bern, Switzerland
[19] Univ Bern, Bern, Switzerland
[20] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[21] Univ Alcala Henares, Madrid, Spain
[22] Univ Athens, Sch Med, GR-11527 Athens, Greece
[23] Univ Bristol, Bristol, Avon, England
[24] Univ Paris 11, UMR 1018, Le Kremlin Bicetre, France
[25] Hop Bicetre, AP HP, Serv Sante Publ, Le Kremlin Bicetre, France
[26] Univ Bordeaux, INSERM, Ctr Inserm Epidemiol & Biostat, U897, Bordeaux, France
[27] Bordeaux Univ Hosp, Dept Internal Med, Bordeaux, France
[28] Inst Salud Carlos III, Consorcio Invest Biomed Epidemiol & Salud Publ CI, Madrid, Spain
[29] Vall dHebron Res Inst, Barcelona, Spain
[30] Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid, Spain
[31] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[32] Harvard Mit Div Hlth Sci & Technol, Boston, MA USA
基金
美国国家卫生研究院;
关键词
INFECTION; MORTALITY; EXPOSURE; IMPACT; RECOMMENDATIONS; ELIGIBILITY; EFAVIRENZ; LOPINAVIR; TENOFOVIR; EVENTS;
D O I
10.1016/S2352-3018(15)00108-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Recommendations have differed nationally and internationally with respect to the best time to start antiretroviral therapy (ART). We compared effectiveness of three strategies for initiation of ART in high-income countries for HIV-positive individuals who do not have AIDS: immediate initiation, initiation at a CD4 count less than 500 cells per mu L, and initiation at a CD4 count less than 350 cells per mu L. Methods We used data from the HIV-CAUSAL Collaboration of cohort studies in Europe and the USA. We included 55 826 individuals aged 18 years or older who were diagnosed with HIV-1 infection between January, 2000, and September, 2013, had not started ART, did not have AIDS, and had CD4 count and HIV-RNA viral load measurements within 6 months of HIV diagnosis. We estimated relative risks of death and of death or AIDS-defining illness, mean survival time, the proportion of individuals in need of ART, and the proportion of individuals with HIV-RNA viral load less than 50 copies per mL, as would have been recorded under each ART initiation strategy after 7 years of HIV diagnosis. We used the parametric g-formula to adjust for baseline and time-varying confounders. Findings Median CD4 count at diagnosis of HIV infection was 376 cells per mu L (IQR 222-551). Compared with immediate initiation, the estimated relative risk of death was 1.02 (95% CI 1.01-1.02) when ART was started at a CD4 count less than 500 cells per mu L, and 1.06 (1.04-1.08) with initiation at a CD4 count less than 350 cells per mu L. Corresponding estimates for death or AIDS-defining illness were 1.06 (1.06-1.07) and 1.20 (1.17-1.23), respectively. Compared with immediate initiation, the mean survival time at 7 years with a strategy of initiation at a CD4 count less than 500 cells per mu L was 2 days shorter (95% CI 1-2) and at a CD4 count less than 350 cells per mu L was 5 days shorter (4-6). 7 years after diagnosis of HIV, 100%, 98.7% (95% CI 98.6-98.7), and 92.6% (92.2-92.9) of individuals would have been in need of ART with immediate initiation, initiation at a CD4 count less than 500 cells per mu L, and initiation at a CD4 count less than 350 cells per mu L, respectively. Corresponding proportions of individuals with HIV-RNA viral load less than 50 copies per mL at 7 years were 87.3% (87.3-88.6), 87.4% (87.4-88.6), and 83.8% (83.6-84.9). Interpretation The benefits of immediate initiation of ART, such as prolonged survival and AIDS-free survival and increased virological suppression, were small in this high-income setting with relatively low CD4 count at HIV diagnosis. The estimated beneficial effect on AIDS is less than in recently reported randomised trials. Increasing rates of HIV testing might be as important as a policy of early initiation of ART.
引用
收藏
页码:E335 / E343
页数:9
相关论文
共 39 条
[1]   EXPANDED EUROPEAN AIDS CASE DEFINITION [J].
ANCELLEPARK, R .
LANCET, 1993, 341 (8842) :441-441
[2]   Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review [J].
Anglemyer, Andrew ;
Rutherford, George W. ;
Easterbrook, Philippa J. ;
Horvath, Tara ;
Vitoria, Marco ;
Jan, Michael ;
Doherty, Meg C. .
AIDS, 2014, 28 :S105-S118
[3]  
[Anonymous], GUID US ANT AG HIV 1
[4]  
[Anonymous], HIV TRIAL FINDS IT B
[5]  
[Anonymous], HSPH PROGRAM CAUSAL
[6]  
[Anonymous], EUR GUID TREATM HIV
[7]  
[Anonymous], EARLY ART IPT HIV IN
[8]   Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study [J].
Babiker, Abdel G. ;
Emery, Sean ;
Faetkenheuer, Gerd ;
Gordin, Fred M. ;
Grund, Birgit ;
Lundgren, Jens D. ;
Neaton, James D. ;
Pett, Sarah L. ;
Phillips, Andrew ;
Touloumi, Giota ;
Vjecha, Michael J. .
CLINICAL TRIALS, 2013, 10 :S5-S36
[9]   Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents [J].
Bedimo, Roger ;
Maalouf, Naim M. ;
Zhang, Song ;
Drechsler, Henning ;
Tebas, Pablo .
AIDS, 2012, 26 (07) :825-831
[10]   When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries An Observational Study [J].
Cain, Lauren E. ;
Logan, Roger ;
Robins, James M. ;
Sterne, Jonathan A. C. ;
Sabin, Caroline ;
Bansi, Loveleen ;
Justice, Amy ;
Goulet, Joseph ;
van Sighem, Ard ;
de Wolf, Frank ;
Bucher, Heiner C. ;
von Wyl, Viktor ;
Esteve, Anna ;
Casabona, Jordi ;
del Amo, Julia ;
Moreno, Santiago ;
Seng, Remonie ;
Meyer, Laurence ;
Perez-Hoyos, Santiago ;
Muga, Roberto ;
Lodi, Sara ;
Lanoy, Emilie ;
Costagliola, Dominique ;
Hernan, Miguel A. .
ANNALS OF INTERNAL MEDICINE, 2011, 154 (08) :509-515